PHARMING GROUP NV (PHARM.AS) Stock Fundamental Analysis
Europe - Euronext Amsterdam - AMS:PHARM - NL0010391025 - Common Stock
1.673 EUR
-0.02 (-1.01%)
Taking everything into account, PHARM scores 5 out of 10 in our fundamental rating. PHARM was compared to 86 industry peers in the Biotechnology industry. Both the profitability and the financial health of PHARM get a neutral evaluation. Nothing too spectacular is happening here. PHARM has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
- PHARM had negative earnings in the past year.
- PHARM had a positive operating cash flow in the past year.
- The reported net income has been mixed in the past 5 years: PHARM reported negative net income in multiple years.
- In multiple years PHARM reported negative operating cash flow during the last 5 years.
1.2 Ratios
- With a decent Return On Assets value of 0.08%, PHARM is doing good in the industry, outperforming 69.77% of the companies in the same industry.
- PHARM has a Return On Equity of 0.14%. This is in the better half of the industry: PHARM outperforms 74.42% of its industry peers.
- With an excellent Return On Invested Capital value of 7.08%, PHARM belongs to the best of the industry, outperforming 84.88% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.08% | ||
| ROE | 0.14% | ||
| ROIC | 7.08% |
ROA(3y)-0.68%
ROA(5y)2.2%
ROE(3y)-1.17%
ROE(5y)5.07%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- PHARM has a better Profit Margin (0.11%) than 70.93% of its industry peers.
- With a decent Operating Margin value of 10.06%, PHARM is doing good in the industry, outperforming 79.07% of the companies in the same industry.
- PHARM's Gross Margin of 89.90% is amongst the best of the industry. PHARM outperforms 84.88% of its industry peers.
- PHARM's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.06% | ||
| PM (TTM) | 0.11% | ||
| GM | 89.9% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.48%
GM growth 5Y0.17%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so PHARM is still creating some value.
- The number of shares outstanding for PHARM has been increased compared to 1 year ago.
- PHARM has more shares outstanding than it did 5 years ago.
- The debt/assets ratio for PHARM has been reduced compared to a year ago.
2.2 Solvency
- PHARM has an Altman-Z score of 1.15. This is a bad value and indicates that PHARM is not financially healthy and even has some risk of bankruptcy.
- PHARM's Altman-Z score of 1.15 is fine compared to the rest of the industry. PHARM outperforms 61.63% of its industry peers.
- The Debt to FCF ratio of PHARM is 2.49, which is a good value as it means it would take PHARM, 2.49 years of fcf income to pay off all of its debts.
- PHARM has a better Debt to FCF ratio (2.49) than 87.21% of its industry peers.
- PHARM has a Debt/Equity ratio of 0.46. This is a healthy value indicating a solid balance between debt and equity.
- With a Debt to Equity ratio value of 0.46, PHARM perfoms like the industry average, outperforming 54.65% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.46 | ||
| Debt/FCF | 2.49 | ||
| Altman-Z | 1.15 |
ROIC/WACC1.26
WACC5.6%
2.3 Liquidity
- PHARM has a Current Ratio of 3.16. This indicates that PHARM is financially healthy and has no problem in meeting its short term obligations.
- The Current ratio of PHARM (3.16) is better than 65.12% of its industry peers.
- A Quick Ratio of 2.39 indicates that PHARM has no problem at all paying its short term obligations.
- With a Quick ratio value of 2.39, PHARM perfoms like the industry average, outperforming 56.98% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.16 | ||
| Quick Ratio | 2.39 |
3. Growth
3.1 Past
- PHARM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 96.30%, which is quite impressive.
- Looking at the last year, PHARM shows a very strong growth in Revenue. The Revenue has grown by 26.78%.
- PHARM shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 10.64% yearly.
EPS 1Y (TTM)96.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%600%
Revenue 1Y (TTM)26.78%
Revenue growth 3Y14.33%
Revenue growth 5Y10.64%
Sales Q2Q%30%
3.2 Future
- The Earnings Per Share is expected to grow by 53.48% on average over the next years. This is a very strong growth
- Based on estimates for the next years, PHARM will show a quite strong growth in Revenue. The Revenue will grow by 8.97% on average per year.
EPS Next Y234.87%
EPS Next 2Y104.54%
EPS Next 3Y59.38%
EPS Next 5Y53.48%
Revenue Next Year26.31%
Revenue Next 2Y14.87%
Revenue Next 3Y10.89%
Revenue Next 5Y8.97%
3.3 Evolution
- The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Forward Earnings ratio is 49.83, which means the current valuation is very expensive for PHARM.
- PHARM's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. PHARM is cheaper than 74.42% of the companies in the same industry.
- The average S&P500 Price/Forward Earnings ratio is at 24.32. PHARM is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 49.83 |
4.2 Price Multiples
- PHARM's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. PHARM is cheaper than 97.67% of the companies in the same industry.
- Based on the Price/Free Cash Flow ratio, PHARM is valued cheaply inside the industry as 98.84% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 2.55 | ||
| EV/EBITDA | 1.28 |
4.3 Compensation for Growth
- PHARM's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- PHARM's earnings are expected to grow with 59.38% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y104.54%
EPS Next 3Y59.38%
5. Dividend
5.1 Amount
- No dividends for PHARM!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
PHARMING GROUP NV / PHARM.AS FAQ
What is the ChartMill fundamental rating of PHARMING GROUP NV (PHARM.AS) stock?
ChartMill assigns a fundamental rating of 5 / 10 to PHARM.AS.
What is the valuation status for PHARM stock?
ChartMill assigns a valuation rating of 5 / 10 to PHARMING GROUP NV (PHARM.AS). This can be considered as Fairly Valued.
Can you provide the profitability details for PHARMING GROUP NV?
PHARMING GROUP NV (PHARM.AS) has a profitability rating of 5 / 10.